Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Published:2021-02-19 Issue:4 Volume:5 Page:1097-1101
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Mohyuddin Ghulam Rehman¹^ORCID,Rooney Anthony¹,Balmaceda Nicole¹,Aziz Muhammad²^ORCID,Sborov Douglas W.³,McClune Brian³,Kumar Shaji K.⁴^ORCID

Affiliation:

1. Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, KS;

2. Division of Gastroenterology, University of Toledo, Toledo, OH;

3. Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT; and

4. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/5/4/1097/1800723/advancesadv2020004017.pdf

Reference36 articles.

1. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management [published correction appears in Am J Hematol. 2020;95(11):1444];Rajkumar;Am J Hematol,2020

2. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement;Moher;PLoS Med,2009

3. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors;Shuster;Res Synthesis Methods,2011

4. Measuring inconsistency in meta-analyses;Higgins;BMJ,2003

5. Chimeric antigen receptor T-cell therapy for multiple myeloma;Atrash;Clin Lymphoma Myeloma Leuk,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma;Annals of Pharmacotherapy;2024-08-27

2. Current status of bispecific antibodies and CAR-T therapies in multiple myeloma;International Immunopharmacology;2024-06

3. Advancing autologous CAR T-cell therapy through real-time patient health data integration: a simulation-based approach;Cytotherapy;2024-05

4. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future;International Journal of Molecular Sciences;2023-10-27

5. Fitness and frailty in myeloma;Hematology;2022-12-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3